Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | PIM1 | P11309 | 1/20 | 0.30 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1607566 | 0.95 | HRH1 (0.32) | HRH1 | |
| SCHEMBL17654219 | 0.91 | — | — | |
| SCHEMBL444346 | 0.76 | DRD2 (0.43) | — | |
| SCHEMBL8829939 | 0.74 | — | — | |
| SCHEMBL1515467 | 0.72 | CYP11B2 (0.41) | SMN1; SMN2 | |
| SCHEMBL16792394 | 0.72 | CYP11B2 (0.37) | — | |
| SCHEMBL467080 | 0.71 | SMN1; SMN2 (0.35) | GAASMN1; SMN2 | |
| SCHEMBL3917224 | 0.71 | MAPK1 (0.34) | — | |
| SCHEMBL874693 | 0.71 | — | — | |
| SCHEMBL1607524 | 0.71 | CYP11B2 (0.44) | GAASMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518975-B2 | Gamma secretase modulators | Merck Sharp + Dohme Corp. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20110082153-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2011-04-07 | — | — | US | disclosed |
| EP-2200990-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009032277-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082153-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | HRH1 2623/4885GAA 11/4885SMN1; SMN2 1223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.